HERON THERAPEUTICS INC (HRTX) Fundamental Analysis & Valuation

NASDAQ:HRTX • US4277461020

Current stock price

1.19 USD
+0.19 (+19.02%)
At close:
1.1996 USD
+0.01 (+0.81%)
After Hours:

This HRTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. HRTX Profitability Analysis

1.1 Basic Checks

  • In the past year HRTX has reported negative net income.
  • HRTX had a negative operating cash flow in the past year.
  • In the past 5 years HRTX always reported negative net income.
  • HRTX had a negative operating cash flow in each of the past 5 years.
HRTX Yearly Net Income VS EBIT VS OCF VS FCFHRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • HRTX has a better Return On Assets (-7.89%) than 82.56% of its industry peers.
  • HRTX's Return On Equity of -140.90% is on the low side compared to the rest of the industry. HRTX is outperformed by 62.60% of its industry peers.
Industry RankSector Rank
ROA -7.89%
ROE -140.9%
ROIC N/A
ROA(3y)-21.14%
ROA(5y)-41.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HRTX Yearly ROA, ROE, ROICHRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 -1K

1.3 Margins

  • HRTX has a Gross Margin of 73.31%. This is amongst the best in the industry. HRTX outperforms 80.81% of its industry peers.
  • HRTX's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for HRTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.35%
GM growth 5Y4.39%
HRTX Yearly Profit, Operating, Gross MarginsHRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. HRTX Health Analysis

2.1 Basic Checks

  • HRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for HRTX has been increased compared to 1 year ago.
  • The number of shares outstanding for HRTX has been increased compared to 5 years ago.
  • HRTX has a better debt/assets ratio than last year.
HRTX Yearly Shares OutstandingHRTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
HRTX Yearly Total Debt VS Total AssetsHRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of -8.82, we must say that HRTX is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of HRTX (-8.82) is worse than 71.90% of its industry peers.
  • HRTX has a Debt/Equity ratio of 9.81. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 9.81, HRTX is not doing good in the industry: 83.33% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 9.81
Debt/FCF N/A
Altman-Z -8.82
ROIC/WACCN/A
WACC8.66%
HRTX Yearly LT Debt VS Equity VS FCFHRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 2.48 indicates that HRTX has no problem at all paying its short term obligations.
  • HRTX's Current ratio of 2.48 is on the low side compared to the rest of the industry. HRTX is outperformed by 71.12% of its industry peers.
  • A Quick Ratio of 1.51 indicates that HRTX should not have too much problems paying its short term obligations.
  • HRTX's Quick ratio of 1.51 is on the low side compared to the rest of the industry. HRTX is outperformed by 81.78% of its industry peers.
Industry RankSector Rank
Current Ratio 2.48
Quick Ratio 1.51
HRTX Yearly Current Assets VS Current LiabilitesHRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. HRTX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 22.22% over the past year.
  • Looking at the last year, HRTX shows a small growth in Revenue. The Revenue has grown by 7.36% in the last year.
  • The Revenue has been growing by 11.82% on average over the past years. This is quite good.
EPS 1Y (TTM)22.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)7.36%
Revenue growth 3Y12.88%
Revenue growth 5Y11.82%
Sales Q2Q%-0.47%

3.2 Future

  • Based on estimates for the next years, HRTX will show a very strong growth in Earnings Per Share. The EPS will grow by 54.91% on average per year.
  • The Revenue is expected to grow by 16.39% on average over the next years. This is quite good.
EPS Next Y100%
EPS Next 2Y92.48%
EPS Next 3Y71.84%
EPS Next 5Y54.91%
Revenue Next Year13.78%
Revenue Next 2Y16.99%
Revenue Next 3Y18.21%
Revenue Next 5Y16.39%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HRTX Yearly Revenue VS EstimatesHRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
HRTX Yearly EPS VS EstimatesHRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 0 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. HRTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for HRTX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HRTX Price Earnings VS Forward Price EarningsHRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HRTX Per share dataHRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as HRTX's earnings are expected to grow with 71.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y92.48%
EPS Next 3Y71.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HRTX Dividend Analysis

5.1 Amount

  • No dividends for HRTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HRTX Fundamentals: All Metrics, Ratios and Statistics

HERON THERAPEUTICS INC

NASDAQ:HRTX (4/24/2026, 8:00:01 PM)

After market: 1.1996 +0.01 (+0.81%)

1.19

+0.19 (+19.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-11
Inst Owners82.9%
Inst Owner Change0.46%
Ins Owners0.78%
Ins Owner Change15.72%
Market Cap224.36M
Revenue(TTM)154.90M
Net Income(TTM)-20.20M
Analysts82.22
Price Target4.42 (271.43%)
Short Float %21.25%
Short Ratio21.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-79.74%
Min EPS beat(2)-161.44%
Max EPS beat(2)1.96%
EPS beat(4)2
Avg EPS beat(4)-2.14%
Min EPS beat(4)-161.44%
Max EPS beat(4)246.99%
EPS beat(8)5
Avg EPS beat(8)25.98%
EPS beat(12)7
Avg EPS beat(12)19.29%
EPS beat(16)9
Avg EPS beat(16)14.84%
Revenue beat(2)1
Avg Revenue beat(2)-1.68%
Min Revenue beat(2)-4.02%
Max Revenue beat(2)0.65%
Revenue beat(4)2
Avg Revenue beat(4)-1.41%
Min Revenue beat(4)-4.22%
Max Revenue beat(4)1.93%
Revenue beat(8)4
Avg Revenue beat(8)-1.26%
Revenue beat(12)5
Avg Revenue beat(12)-0.94%
Revenue beat(16)8
Avg Revenue beat(16)0.33%
PT rev (1m)0%
PT rev (3m)-3.7%
EPS NQ rev (1m)-100%
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)100%
Revenue NQ rev (1m)-4.4%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.45
P/FCF N/A
P/OCF N/A
P/B 15.65
P/tB 15.65
EV/EBITDA N/A
EPS(TTM)-0.07
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0.82
BVpS0.08
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -7.89%
ROE -140.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.31%
FCFM N/A
ROA(3y)-21.14%
ROA(5y)-41.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.35%
GM growth 5Y4.39%
F-Score3
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 9.81
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.7%
Cap/Sales 0.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.48
Quick Ratio 1.51
Altman-Z -8.82
F-Score3
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)45.15%
Cap/Depr(5y)59.75%
Cap/Sales(3y)0.87%
Cap/Sales(5y)1.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y100%
EPS Next 2Y92.48%
EPS Next 3Y71.84%
EPS Next 5Y54.91%
Revenue 1Y (TTM)7.36%
Revenue growth 3Y12.88%
Revenue growth 5Y11.82%
Sales Q2Q%-0.47%
Revenue Next Year13.78%
Revenue Next 2Y16.99%
Revenue Next 3Y18.21%
Revenue Next 5Y16.39%
EBIT growth 1Y77.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.47%
OCF growth 3YN/A
OCF growth 5YN/A

HERON THERAPEUTICS INC / HRTX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of HERON THERAPEUTICS INC (HRTX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to HRTX.


What is the valuation status for HRTX stock?

ChartMill assigns a valuation rating of 1 / 10 to HERON THERAPEUTICS INC (HRTX). This can be considered as Overvalued.


How profitable is HERON THERAPEUTICS INC (HRTX) stock?

HERON THERAPEUTICS INC (HRTX) has a profitability rating of 2 / 10.


Can you provide the financial health for HRTX stock?

The financial health rating of HERON THERAPEUTICS INC (HRTX) is 2 / 10.


What is the earnings growth outlook for HERON THERAPEUTICS INC?

The Earnings per Share (EPS) of HERON THERAPEUTICS INC (HRTX) is expected to grow by 100% in the next year.